Application of next-generation sequencing in gastrointestinal and liver tumors

Sameh Mikhail, Bishoy Faltas, Mohamed E. Salem, Tanios Bekaii-Saab

Research output: Contribution to journalShort survey

3 Citations (Scopus)

Abstract

Malignant transformation of normal cells is associated with the evolution of genomic alterations. This concept has led to the development of molecular testing platforms to identify genomic alterations that can be targeted with novel therapies. Next generation sequencing (NGS) has heralded a new era in precision medicine in which tumor genes can be studied efficiently. Recent developments in NGS have allowed investigators to identify genomic predictive makers and hereditary mutations to guide treatment decision. The application of NGS in gastrointestinal cancers is being extensively studied but continues to face substantial challenges. In our review, we discuss various NGS platforms and highlight their role in identifying familial mutations and markers of response or resistance to cancer therapy. We also provide a balanced discussion of the challenges that limit the routine use of NGS in clinical practice.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalCancer Letters
Volume374
Issue number2
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Liver
Neoplasms
Precision Medicine
Mutation
Gastrointestinal Neoplasms
Therapeutics
Research Personnel
Genes

Keywords

  • Challenges
  • Clinical application
  • Gastrointestinal cancer
  • Next generation sequencing
  • Predictive markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Application of next-generation sequencing in gastrointestinal and liver tumors. / Mikhail, Sameh; Faltas, Bishoy; Salem, Mohamed E.; Bekaii-Saab, Tanios.

In: Cancer Letters, Vol. 374, No. 2, 01.05.2016, p. 187-191.

Research output: Contribution to journalShort survey

Mikhail, Sameh ; Faltas, Bishoy ; Salem, Mohamed E. ; Bekaii-Saab, Tanios. / Application of next-generation sequencing in gastrointestinal and liver tumors. In: Cancer Letters. 2016 ; Vol. 374, No. 2. pp. 187-191.
@article{7fbb66539bc54802a83a4776653093a9,
title = "Application of next-generation sequencing in gastrointestinal and liver tumors",
abstract = "Malignant transformation of normal cells is associated with the evolution of genomic alterations. This concept has led to the development of molecular testing platforms to identify genomic alterations that can be targeted with novel therapies. Next generation sequencing (NGS) has heralded a new era in precision medicine in which tumor genes can be studied efficiently. Recent developments in NGS have allowed investigators to identify genomic predictive makers and hereditary mutations to guide treatment decision. The application of NGS in gastrointestinal cancers is being extensively studied but continues to face substantial challenges. In our review, we discuss various NGS platforms and highlight their role in identifying familial mutations and markers of response or resistance to cancer therapy. We also provide a balanced discussion of the challenges that limit the routine use of NGS in clinical practice.",
keywords = "Challenges, Clinical application, Gastrointestinal cancer, Next generation sequencing, Predictive markers",
author = "Sameh Mikhail and Bishoy Faltas and Salem, {Mohamed E.} and Tanios Bekaii-Saab",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.canlet.2016.02.029",
language = "English (US)",
volume = "374",
pages = "187--191",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Application of next-generation sequencing in gastrointestinal and liver tumors

AU - Mikhail, Sameh

AU - Faltas, Bishoy

AU - Salem, Mohamed E.

AU - Bekaii-Saab, Tanios

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Malignant transformation of normal cells is associated with the evolution of genomic alterations. This concept has led to the development of molecular testing platforms to identify genomic alterations that can be targeted with novel therapies. Next generation sequencing (NGS) has heralded a new era in precision medicine in which tumor genes can be studied efficiently. Recent developments in NGS have allowed investigators to identify genomic predictive makers and hereditary mutations to guide treatment decision. The application of NGS in gastrointestinal cancers is being extensively studied but continues to face substantial challenges. In our review, we discuss various NGS platforms and highlight their role in identifying familial mutations and markers of response or resistance to cancer therapy. We also provide a balanced discussion of the challenges that limit the routine use of NGS in clinical practice.

AB - Malignant transformation of normal cells is associated with the evolution of genomic alterations. This concept has led to the development of molecular testing platforms to identify genomic alterations that can be targeted with novel therapies. Next generation sequencing (NGS) has heralded a new era in precision medicine in which tumor genes can be studied efficiently. Recent developments in NGS have allowed investigators to identify genomic predictive makers and hereditary mutations to guide treatment decision. The application of NGS in gastrointestinal cancers is being extensively studied but continues to face substantial challenges. In our review, we discuss various NGS platforms and highlight their role in identifying familial mutations and markers of response or resistance to cancer therapy. We also provide a balanced discussion of the challenges that limit the routine use of NGS in clinical practice.

KW - Challenges

KW - Clinical application

KW - Gastrointestinal cancer

KW - Next generation sequencing

KW - Predictive markers

UR - http://www.scopus.com/inward/record.url?scp=84975761208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975761208&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.02.029

DO - 10.1016/j.canlet.2016.02.029

M3 - Short survey

C2 - 26916979

AN - SCOPUS:84975761208

VL - 374

SP - 187

EP - 191

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -